Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema
Bushra Mushtaq,1,* Niall J Crosby,1,* Antonios T Dimopoulos,1 Peck Lin Lip,1 Panagiota Stavrou,1 Samer El-Sherbiny,1 Yit Yang2 1Birmingham and Midland Eye Centre, City and Sandwell National Health Service Trust, Birmingham, West Midlands, UK; 2Life and Health Sciences, Aston University, Birmingham,...
Guardado en:
Autores principales: | Mushtaq B, Crosby NJ, Dimopoulos AT, Lip PL, Stavrou P, El-Sherbiny S, Yang Y |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a2c2d02d3f7148f28eceb79540be5ec2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
One-year outcome of bevacizumab therapy for chronic macular edema in central and branch retinal vein occlusions in real-world clinical practice in the UK
por: Lip PL, et al.
Publicado: (2015) -
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017) -
Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
por: Juan Carlos Mesa Gutiérrez, et al.
Publicado: (2008) -
Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
por: Thapa R, et al.
Publicado: (2012) -
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
por: Demir M, et al.
Publicado: (2011)